Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reineckia-biflavone A (RFA) is a novel biflavone compound isolated from *Reineckia carnea* Kunth, a traditional medicinal herb used by the Miao nationality in southwest China. It has demonstrated potent antiproliferative activity against renal cell carcinoma (RCC) cells, specifically the 786-O cell line, with an IC50 of 19.34 μmol/L. RFA induces apoptosis through the mitochondrial pathway, characterized by the up-regulation of pro-apoptotic proteins such as Bax, Caspase-3, and Cytochrome c, and the down-regulation of the anti-apoptotic protein Bcl-2. Additionally, it triggers S-phase cell cycle arrest, increases intracellular calcium levels, and decreases mitochondrial membrane potential. Notably, it shows minimal cytotoxicity toward red blood cells and peripheral blood mononuclear cells, suggesting potential selectivity for cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on reineckia-biflavone a.